BIIB•benzinga•
Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook
Summary
Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 12, 2025 by benzinga